Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q44298735)

1 December 2017

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

1 December 2017

P G Casali

1

1 reference

PubMed ID

20555113

1 December 2017

J-Y Blay

series ordinal

2

1 reference

PubMed ID

20555113

1 December 2017

ESMO/CONTICANET/EUROBONET Consensus Panel of Experts

series ordinal

3

1 reference

1 December 2017

1 May 2010

1 reference

1 December 2017

1 reference

1 December 2017

21 Suppl 5

1 reference

1 December 2017

v98-102

1 reference

We should desist using RECIST, at least in GIST.

1 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ208

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ208

1 reference

1 December 2017

1 reference

PubMed ID

20555113